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Abstract
Background: The purpose herein, was to perform a systematic review of interventional outcome 
studies in patients with in-hospital cardiac arrest before and during the coronavirus disease 2019 
(COVID-19) pandemic period.
Methods: A meta-analysis was performed of publications meeting the following PICOS criteria:  
(1) participants, patients > 18 years of age with cardiac arrest due to any causes; (2) intervention, car-
diac arrest in COVID-19 period; (3) comparison, cardiac arrest in pre-COVID-19 period; (4) outcomes, 
detailed information for survival; (5) study design, randomized controlled trials, quasi-randomized or 
observational studies comparing cardiac arrest in COVID-19 and pre-COVID-19 period for their effects 
in patients with cardiac arrest. 
Results: Survival to hospital discharge for the pre-pandemic and pandemic period was reported in 
3 studies (n =1432 patients) and was similar in the pre-pandemic vs. the pandemic period, 35.6% 
vs. 32.1%, respectively (odds ratio [OR] 1.72; 95% confidence interval [CI] 0.81–3.65; p = 0.16;  
I2 = 72%). Return of spontaneous circulation was reported by all 4 studies and were also similar in the 
pre and during COVID-19 periods, 51.9% vs. 48.7% (OR 1.27; 95% CI 0.78–2.07; p = 0.33; I2 = 71%),  
respectively. Pooled analysis of cardiac arrest recurrence was also similar, 24.9% and 17.9% (OR 
1.60; 95% CI 0.99–2.57; p = 0.06; I2 = 32%) in the pre and during COVID-19 cohorts. Survival with  
Cerebral Performance Category 1 or 2 was higher in pre vs. during pandemic groups (27.3 vs. 9.1%; 
OR 3.75; 95% CI 1.26–11.20; p = 0.02). Finally, overall mortality was similar in the pre vs. pandemic 
groups, 65.9% and 67.2%, respectively (OR 0.67; 95% CI 0.33–1.34; p = 0.25; I2 = 76%).
Conclusions: Compared to the pre-pandemic period, in hospital cardiac arrest in COVID-19 patients 
was numerically higher but had statistically similar outcomes. (Cardiol J 2021; 28, 4: 503–508)
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In December 2019 the coronavirus disease 
(COVID-19) emerged in Wuhan, China and spread 
rapidly throughout the world causing a pandemic 
[1]. As of March 2021, there were over 126 mil-
lion confirmed cases and over 2.7 million deaths 
worldwide [2].
Clinically, severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2), the virus responsi-
ble for COVID-19, manifests with wide variability 
ranging from being asymptomatic to severe re-
spiratory failure and death. An estimated 14% of 
patients with COVID-19 require hospitalization, 
with 2% requiring intensive care [3]. While coexis-
ting conditions, such as, hypertension, diabetes, 
cardiovascular disease, obesity, chronic obstructive 
pulmonary disease and chronic renal failure have 
been associated with poor prognosis [4], respirato-
ry failure is the leading cause of admission to the 
intensive care unit (ICU) [5]. Further, studies show 
that the mortality rate in the ICU can be greater 
than 35% [6], and the leading cause of such high 
mortality is in-hospital cardiac arrest (IHCA) [7]. 
To understand the role of COVID-19 on out-
comes of IHCA, we designed a systematic review 
of studies in adults during versus pre-pandemic pe-
riods of patients who suffered from cardiac arrest.
Methods
The study was performed following the rec-
ommendation Preferred Reporting Items for Sys-
tematic Reviews and Meta-Analyses (PRISMA) 
statement for reporting systematic reviews and 
meta-analyses [8]. Before starting the study, there 
was agreement on the analysis methods and the 
inclusion and exclusion criteria to be used. Because 
of its nature, this study was exempt from an insti-
tutional board review.
Inclusion and exclusion criteria
Studies included in this meta-analysis met 
the following PICOS criteria: (1) Participants: 
patients > 18 years of age with cardiac arrest due 
to any causes, (2) Intervention: cardiac arrest in 
COVID-19 period, (3) Comparison: cardiac arrest 
in pre-COVID-19 period, (4) Outcomes: detailed 
information for survival, (5) Study design: ran-
domized controlled trials, quasi-randomized or 
observational studies comparing cardiac arrest 
during and before the COVID-19 period for their 
effects in patients with cardiac arrest. Studies were 
excluded if they were reviews, case reports, confer-
ence or poster abstracts, or articles not containing 
original data.
Search strategy
A computerized search of the Medline (Pub-
Med), Embase, Cochrane Central Register of 
Controlled Trials (CENTRAL), Scopus, Web of 
Science was performed from inception to Febru-
ary 2nd, 2021. Titles and abstracts were screened 
by two authors independently (A.G. and M.P.). All 
retrieved articles were reviewed by two authors 
(J.S. and M.C.). Any disagreement was resolved 
through consensus or, if necessary, by discussion 
with a third author (L.S.).
The search was performed using the following 
terms: “cardiac arrest” OR “CA” OR “heart arrest” 
OR “circulation arrest” OR “cardiopulmonary 
resuscitation” OR “CPR” OR “in-hospital cardiac 
arrest” OR “IHCA” OR “return of spontaneous 
circulation” OR “ROSC” OR “cardiac ventric* 
fibrillation” OR “heart ventric* fibrillation” OR 
“pulseless ventric* tachycardia” OR “asysto*” 
OR “pulseless electrical activity” OR “PEA” AND 
“SARS-CoV-2” OR “COVID-19”. Bibliographies of 
retrieved articles were manually checked for ad-
ditional references to identify all eligible studies 
and achieve minimal publication bias. Only full ar-
ticles in the English language were considered. All 
references were saved in an EndNote (EndNote, 
Inc., Philadelphia, PA, USA) library that was used 
to identify duplicates. 
Data extraction
Information was recorded on study char-
acteristics and demographics such as authors, 
publication year, inclusion and exclusion criteria, 
primary outcome, findings, as well as per group 
sample size and outcomes. Two reviewers (A.G., 
M.J.J.) independently abstracted data, which a third 
investigator (L.S.) independently verified. Authors 
of articles were contacted when data were missing 
or were reported in a format that did not allow sta-
tistical analysis. Care was taken to avoid inclusion 
of data from duplicate publications. In the case of 
suspected data discrepancies, the relevant author 
was contacted directly. Moreover, each reviewer 
performed independent data abstraction, using 
a standardized predefined data collection form.
Quality assessment
Two investigators (A.G. and L.S.) independent-
ly extracted individual study data and evaluated the 
studies for risk of bias. Any disagreements were 
discussed and resolved in a consensus meeting 
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with the third reviewer (M.J.J.). The ROBINS-I 
tool (Risk of Bias in Non-randomized Studies — 
of Interventions) was used to assess the quality 
of studies [9]. Robvis application was used to for 
visualize risk-of-bias assessments [10]. The scale 
has seven main domains (confounding, participant 
selection, classification of interventions, deviation 
from interventions, missing data, outcome mea-
surement, and selection of reported results) and 
assigns one point for each of four judgements, 
which are rated as critical, serious, moderate or 
low (Suppl. Fig. S3 and Fig. S4). 
Outcomes
The following outcomes were evaluated in the 
analysis, based on the consensus among content 
experts in our group with regard to important out-
comes. The primary outcome was survival to hos-
pital discharge, or 30 days (SHD), whichever came 
first. Secondary outcomes were return of spontane-
ous circulation (ROSC), recurrence of cardiac arrest, 
survival with favorable neurologic status (defined 
as a survival with Cerebral Performance Category 
[CPC] 1 or 2), and overall mortality.
Statistical analysis
Statistical analysis was performed using Re-
view Manager software (v.5.4, Nordic Cochrane 
Center, The Cochrane Collaboration, Copenhagen, 
Denmark). The Mantel-Haenszel method was used 
to analyze dichotomous outcomes, and results are 
reported as odds ratios (ORs) with 95% confidence 
interval (CI). Continuous outcome differences were 
analyzed using an inverse variance model with 
a 95% CI, and values are reported as mean differ-
ence. When the continuous outcome was reported 
in a study as median, range, and interquartile range, 
means and standard deviations were estimated 
using the formula described by Hozo et al. [11]. 
All p values were two-tailed and considered 
significant if < 0.05. Heterogeneity was quantified 
in each analysis by the tau-squared and I-squared 
statistics. Heterogeneity was detected with the 
chi-squared test with n – 1 degree of freedom, which 
was expressed as I2. Values of I2 > 50% and > 75% 
were considered to indicate moderate and significant 
heterogeneity among studies, respectively. 
Results
Study characteristics
A total of 4 studies [12–15], reporting on 1609 
patients (n = 788 pre and n = 821 pandemic pa-
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similar, rate in the pre-pandemic vs. the pandemic 
period, 35.6% vs. 32.1%, respectively (OR 1.72; 
95% CI 0.81–3.65; p = 0.16; I2 = 72%). ROSC was 
reported by all 4 studies, with a similar numerically 
higher but statistically similar relationship, 51.9% 
vs. 48.7% (OR 1.27; 95% CI 0.78–2.07; p = 0.33; 
I2 = 71%), for the pre and during COVID-19 periods, 
respectively (Supplementary digital file). Pooled 
analysis of cardiac found an arrest recurrence of 
Figure 1. Flow diagram showing stages of database searching and study selection as per Preferred Reporting Items 
for Systematic reviews and Meta-analysis (PRISMA) guideline.
Figure 2. Forest plot of return of survival to hospital discharge between pre-pandemic versus pandemic group. The 
center of each square represents the weighted odds ratios for individual trials, and the corresponding horizontal line 
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     (n = 8)
— non-comparative (n = 5)











Records after duplicates removed
(n = 733)
Suppl. Table S1). The PRISMA flowchart (Fig. 1) 
summarizes the outcomes of the search strategy. 
Outcomes pre-pandemic vs. pandemic period
A pooled analysis of all outcomes is presented 
on Figure 2 and Supplemental Figures S1 and S2. 
SHD for the pre-pandemic and pandemic period 
was reported in 3 studies (n = 1432 patients). It 
occurred at a numerically higher, but a statistically 
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24.9% and 17.9% (OR 1.60; 95% CI 0.99–2.57; 
p = 0.06; I2 = 32%) in the pre and during COVID-19 
cohorts, respectively. Survival with CPC 1 or 2 was 
reported only by Yuriditsky et al. [15] and was sig-
nificantly higher in pre-pandemic group compared 
with pandemic group (27.3 vs. 9.1%; OR 3.75; 
95% CI 1.26–11.20; p = 0.02). Overall mortality in 
pre-pandemic vs. pandemic group was 65.9% and 
67.2%, respectively (OR 0.67; 95% CI 0.33–1.34; 
p = 0.25; I2 = 76%).
Outcomes in pandemic period
Only 1 study was found, Sultanian et al. [14], 
that compared IHCA outcomes in pandemic period 
between COVID-19 and non-COVID-19 patients. 
In this study SHD between COVID-19 and non-
-COVID-19 patients was 25.0% vs. 41.8% (OR 
0.46; 95% CI 0.26–0.83; p = 0.01). In the case of 
COVID-19 patients there was a significantly lower 
ROSC rate compared with non-COVID-19 patients 
(30.5% vs. 52.6%, respectively; OR 0.40; 95% 
CI 0.23–0.69; p = 0.001). Ultimately, the overall 
mortality in the COVID-19 patients was 75.0% and 
was significantly higher than that in non-COVID-19 
patients — 59.3% (OR 2.06; 95% CI 1.15–3.69; 
p = 0.02). Finally, overall mortality in the present 
analysis was similar in the pre vs. pandemic groups, 
65.9% and 67.2%, respectively (OR 0.67; 95% CI 
0.33–1.34; p = 0.25; I2 = 76%).
Discussion
According to available research, this is the 
first meta-analysis comparing characteristics and 
outcomes of IHCA before and during the COVID-19 
pandemic. The primary outcome of the study was 
to measure the survival to hospital discharge or 
30 days, whichever came first, although it was ex-
pected that mortality rates would be higher during 
the pandemic, it was found that the survival rates 
were similar to the pre-pandemic period. There 
are possible explanations of this phenomenon. 
During the pre-pandemic time the vast majority 
of the IHCA happened in the ICU [16], commonly 
the result of complications from cardiovascular 
disease, while during the pandemic a shift of IHCA 
occurring in the standard ward as a result of the 
pulmonary inflammatory state and fibrosis of the 
lung tissue [14] was observed [13]. 
Sustained ROSC was found, defined as stable 
circulation for at least 20 min [13] was similar in the 
pre-pandemic period. Interestingly in the cohort 
by Miles et al. [12] the pre-pandemic group was 
characterized by much higher ROSC. Although 
ROSC is generally a positive predictor of survival 
[17], Sheth et al. [18] presented data which showed 
that although all patients with COVID-19 who suf-
fered cardiac arrest and achieved ROSC did not 
achieve SHD.
Consistent with the current primary outcome, 
a insignificant trend was found (p = 0.06) of lower 
recurrence of cardiac arrest in the pandemic group. 
This finding is also likely the result of the different 
etiology of cardiac arrests in the pre and during 
pandemic periods. In the pre pandemic period the 
vast majority of IHCA was caused by the underlying 
cardiac diseases [19] as opposed to the respiratory 
background in the COVID-19 era.  
In his paper Yuriditsky et al. [15] assessed the 
functional status using the CPC. This score ranges 
from 1 (good cerebral performance) to 5 (brain 
death), with CPC 1 and 2 generally categorized as 
good neurological outcome and 3 to 5 as poor [20]. 
It was reported that the pre pandemic group had 
a statistically significant higher survival with CPC 1 
or 2 amounting to 27.3% vs. 9.1% in the COVID-19 
cohort. A possible explanation may lie in the loca-
tion of IHCA resuscitation. In the pre-pandemic 
period, many resuscitations occurred in an ICU, 
where early identification and greater resources 
may result in better outcomes than general ward 
resuscitations that are found later and may have 
fewer resources.
When comparing COVID vs. non-COVID, 
there was lower SHD in COVID patients, 25.0% 
vs. 41.8%, respectively [14]. This may be because 
COVID patients were less likely to have a cardiac 
cause of the arrest, and a respiratory cause was 
more likely. Such a high discrepancy might be 
the result of the burden of critical illness with 
a higher likelihood or requiring ICU admission, 
invasive mechanical ventilation, vasopresors or re-
nal replacement therapies than the non-COVID-19 
cohort [21, 22]. 
Sultanian et al. [14] also reports statistically 
significantly lower ROSC rate for COVID-19 posi-
tive cohort with only 7.6% of patients presenting 
with the shockable rhythm. Overall mortality 
among the COVID-19 patients was 75.0% and was 
significantly higher than the 59.3% that occurred 
in non-COVID-19 patients.
Limitations of the study
Although a limitation of the present study 
was the strict inclusion criteria, which allowed for 
the inclusion of only 4 papers, it did insure a high 
quality of results in over 1600 patients. A second 
limitation is the focus on general epidemiologic 
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findings, which does not allow for the pinpointing 
of the specific risk factors that could be used as 
a guideline for the selection of high-risk patients. 
Conclusions
It was found that the IHCA before and during 
the COVID-19 pandemic had numerically higher 
but statistically similar outcomes.
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